0
0

Seniors’ Access to Critical Medications Act of 2024

10/4/2024, 8:07 PM

Summary of Bill HR 5526

The Seniors’ Access to Critical Medications Act of 2024, introduced in the 118th Congress on September 18, 2023, aims to address seniors' access to essential medications. The bill, designated as H.R. 5526, focuses on improving and ensuring the availability of critical medications for senior citizens. Specific provisions within the bill intend to enhance seniors' access to these vital medications, potentially through measures such as affordability initiatives, regulatory improvements, or healthcare system enhancements. Further details on the specific directives or actions proposed in the bill can be found in the official documents linked through the provided URLs.

Congressional Summary of HR 5526

Seniors’ Access to Critical Medications Act of 2024

This bill temporarily allows physicians to dispense outpatient prescription drugs and related supplies under the Medicare prescription drug benefit to patients via mail or to their caregivers without violating certain prohibitions under the Stark law (i.e., the Physician Self-Referral Law), if certain conditions are met. It also allows for coverage of certain external infusion pumps and associated home infusion drugs under Medicare.

Current law requires physicians to dispense outpatient prescription drugs and related supplies to patients in their office buildings in order to qualify for an exception (the in-office ancillary services exception) under the Stark law. The bill specifies that, from January 1, 2025 to December 31, 2029, physicians may dispense outpatient prescription drugs and related supplies to their patients via mail, and individuals or their family members or caregivers may pick up such items at the physician's office building, if the individual (1) had a face-to-face visit with the prescriber in the prior year, not including telehealth visits; (2) the prescriber furnished other items or services to the individual in the prior year; and (3) the prescriber has an ongoing professional relationship with the individual. 

In addition, the bill specifies that external infusion pumps and associated home infusion drugs may be covered under Medicare even if they don't meet certain regulatory requirements, if these items are provided in accordance with the bill's specified criteria, including that the drug is administered under the supervision of a qualified home infusion therapy supplier.

Current Status of Bill HR 5526

Bill HR 5526 is currently in the status of Introduced to Senate since September 24, 2024. Bill HR 5526 was introduced during Congress 118 and was introduced to the House on September 18, 2023.  Bill HR 5526's most recent activity was Received in the Senate and Read twice and referred to the Committee on Finance. as of September 24, 2024

Bipartisan Support of Bill HR 5526

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
69
Democrat Cosponsors
29
Republican Cosponsors
40
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5526

Primary Policy Focus

Health

Potential Impact Areas

- Government information and archives
- Internet, web applications, social media
- Medicare
- Prescription drugs

Alternate Title(s) of Bill HR 5526

Seniors’ Access to Critical Medications Act of 2024
Seniors’ Access to Critical Medications Act of 2024
Seniors’ Access to Critical Medications Act of 2024
To amend title XVIII of the Social Security Act to clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for covered outpatient drugs furnished under the Medicare program, and to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under such program
Seniors’ Access to Critical Medications Act of 2024
Seniors’ Access to Critical Medications Act of 2023
To amend title XVIII of the Social Security Act to clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program.

Comments